KYORIN Pharmaceutical Co., Ltd. (TYO:4569)
Japan · Delayed Price · Currency is JPY 1,080.00
+4.00 (0.37%)
Nov 13, 2026, 3:30 PM JST
KYORIN Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 125,015 | 126,257 | 130,087 | 119,532 | 113,270 | 105,534 | |
Revenue Growth | -6.48% | -2.94% | 8.83% | 5.53% | 7.33% | 2.56% |
Cost of Revenue | 75,906 | 74,634 | 70,551 | 68,124 | 63,102 | 56,093 |
Gross Profit | 49,109 | 51,623 | 59,536 | 51,408 | 50,168 | 49,441 |
Selling, General & Admin | 34,539 | 35,995 | 36,453 | 37,375 | 34,140 | 35,536 |
Research & Development | 12,060 | 12,060 | 10,514 | 8,019 | 10,903 | 8,897 |
Operating Expenses | 46,608 | 48,114 | 46,989 | 45,402 | 45,047 | 44,437 |
Operating Income | 2,501 | 3,509 | 12,547 | 6,006 | 5,121 | 5,004 |
Interest Expense | -248 | -254 | -173 | -66 | -66 | -66 |
Interest & Investment Income | 592 | 518 | 497 | 500 | 465 | 410 |
Earnings From Equity Investments | 44 | 35 | 38 | -12 | - | 25 |
Currency Exchange Gain (Loss) | 198 | 171 | 165 | 59 | 78 | 98 |
Other Non Operating Income (Expenses) | 51 | 51 | 144 | 114 | 228 | 97 |
EBT Excluding Unusual Items | 3,138 | 4,030 | 13,218 | 6,601 | 5,826 | 5,568 |
Gain (Loss) on Sale of Investments | -153 | 368 | -305 | 1,403 | 70 | -320 |
Gain (Loss) on Sale of Assets | -2,561 | -48 | -127 | -90 | -15 | -32 |
Asset Writedown | - | - | - | - | -257 | - |
Other Unusual Items | 98 | 100 | -16 | -896 | 1,281 | - |
Pretax Income | 522 | 4,450 | 12,770 | 7,018 | 6,905 | 5,216 |
Income Tax Expense | 134 | 1,002 | 3,684 | 1,696 | 2,182 | 1,284 |
Net Income | 388 | 3,448 | 9,086 | 5,322 | 4,723 | 3,932 |
Net Income to Common | 388 | 3,448 | 9,086 | 5,322 | 4,723 | 3,932 |
Net Income Growth | -95.84% | -62.05% | 70.73% | 12.68% | 20.12% | -35.86% |
Shares Outstanding (Basic) | 57 | 57 | 57 | 57 | 57 | 57 |
Shares Outstanding (Diluted) | 57 | 57 | 57 | 57 | 57 | 57 |
Shares Change | 0.02% | -0.00% | 0.10% | 0.15% | 0.00% | 0.01% |
EPS (Basic) | 6.75 | 60.02 | 158.16 | 92.73 | 82.42 | 68.62 |
EPS (Diluted) | 6.75 | 60.02 | 158.16 | 92.73 | 82.42 | 68.62 |
EPS Growth | -95.84% | -62.05% | 70.55% | 12.51% | 20.11% | -35.86% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 8,748 | 2,517 | -2,191 | -4,229 | -4,322 | 3,902 |
Free Cash Flow Per Share | 152.25 | 43.81 | -38.14 | -73.69 | -75.42 | 68.09 |
Dividend Per Share | 37.000 | 57.000 | 52.000 | 52.000 | 52.000 | 52.000 |
Dividend Growth | -28.85% | 9.62% | 0% | 0% | 0% | -30.67% |
Gross Margin | 39.28% | 40.89% | 45.77% | 43.01% | 44.29% | 46.85% |
Operating Margin | 2.00% | 2.78% | 9.64% | 5.03% | 4.52% | 4.74% |
Profit Margin | 0.31% | 2.73% | 6.98% | 4.45% | 4.17% | 3.73% |
Free Cash Flow Margin | 7.00% | 1.99% | -1.68% | -3.54% | -3.82% | 3.70% |
EBITDA | 7,185 | 8,172 | 17,150 | 10,296 | 8,961 | 8,718 |
EBITDA Margin | 5.75% | 6.47% | 13.18% | 8.61% | 7.91% | 8.26% |
D&A For EBITDA | 4,684 | 4,663 | 4,603 | 4,290 | 3,840 | 3,714 |
EBIT | 2,501 | 3,509 | 12,547 | 6,006 | 5,121 | 5,004 |
EBIT Margin | 2.00% | 2.78% | 9.64% | 5.03% | 4.52% | 4.74% |
Effective Tax Rate | 25.67% | 22.52% | 28.85% | 24.17% | 31.60% | 24.62% |
Advertising Expenses | - | 4,616 | 4,589 | 5,593 | 4,714 | 4,731 |